MedTrace Logo

Observational Registry Study of Quality of Life When Treating BTcP With Abstral

NCT01936636 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 164

Last updated 2015-11-05

No results posted yet for this study

Summary

This Observational Registry study is designed to collect self-reported Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program-enrolled patient experience with breakthrough cancer pain (BTcP) as a result of treatment with Abstral® through the use of Quality of Life and pain measurement tools administered via questionnaire.

Conditions

  • Quality of Life
  • Breakthrough Cancer Pain

Interventions

DRUG

Fentanyl

Sponsors & Collaborators

  • Galena Biopharma, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01936636 on ClinicalTrials.gov